Mesoblast - Stock Price History | MESO

Historical daily share price chart and data for Mesoblast since 2021 adjusted for splits. The latest closing stock price for Mesoblast as of September 27, 2021 is 6.29.
  • The all-time high Mesoblast stock closing price was 19.81 on August 17, 2020.
  • The Mesoblast 52-week high stock price is 18.80, which is 198.9% above the current share price.
  • The Mesoblast 52-week low stock price is 5.83, which is 7.3% below the current share price.
  • The average Mesoblast stock price for the last 52 weeks is 9.25.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Mesoblast Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 11.6458 7.8300 19.8100 3.3800 8.4900 15.20%
2019 5.4445 4.4900 7.4200 4.1900 7.3700 78.88%
2018 5.9479 5.8400 8.6000 3.5100 4.1200 -29.45%
2017 7.1339 5.4000 12.3400 4.9100 5.8400 9.16%
2016 5.8243 6.1800 10.5400 3.5400 5.3500 -15.88%
2015 6.1124 8.1100 8.1100 4.8000 6.3600 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.816B $0.007B
Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29